SmartCells logo — Innovative insulin solutions for diabetes and advanced polym...

SmartCells

Innovative insulin solutions for diabetes and advanced polymer-based dosing for comprehensive medical applications.

Founded 2003 Series D Total: $10.72M Biotechnology, Health Care

General Information

Company Name SmartCells
Founded Year 2003
Industries Biotechnology, Health Care
Funding Stage Series D
Social

BounceWatch is an independent company data service, not affiliated with SmartCells. To contact SmartCells, visit smartinsulin.com.

Is this your company?

Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.

Get Verified

How does SmartCells compare?

A PDF of SmartCells and up to 10 competitors you pick: team, funding, traffic and every dated move of the last 90 days. Each company is re-checked on the day you order, so it is current.

See a sample report

This takes a few seconds: we look beyond our own index too.

Meeting SmartCells soon?

A one-page PDF brief: what it does, key facts, the last 90 days of dated moves and questions worth asking. Re-checked on the day you order. See a sample

About SmartCells

SmartCells, Inc. is a biotechnology company founded in 2003 with a focus on developing innovative solutions for diabetes and other medical applications. The company's flagship product, SmartInsulin, is a self-regulating injectable insulin formulation designed to improve diabetes management. In addition to diabetes, SmartCells' advanced polymer-based dosing technology has potential applications in addressing a variety of medical needs, including fertility, thyroid, and growth hormone deficiencies. The company also seeks to tackle challenges in treatment compliance and therapeutic window issues in areas such as oncology and drug-device combinations. SmartCells, Inc. received a significant $4.10M Series D investment on 16 June 2010, with funding contributed by notable investors including Beacon Angels, Boston Harbor Angels, Cherrystone Angel Group, Angel Healthcare Investors, and CVP Management. The company, headquartered in Beverly, Massachusetts, continues to demonstrate potential for growth and impact in the biotechnology and healthcare industries. With its focus on addressing critical medical needs and its track record of attracting investments from respected angel and venture capital groups, SmartCells, Inc. stands as a compelling player in the evolving landscape of medical innovation and treatments.

Business keywords: insulin products, diabetes management, injectable formulation, polymer-based dosing, medical applications, fertility treatment, thyroid treatment, growth hormone deficiencies, oncology treatments, drug-device combinations, innovation, healthcare solutions, compliance management

Funding Rounds & Investors (10)

View All
Funding Stage Amount Investors Lead Investors Date
Series D $4.10M 5
Beacon Angels, Boston Harbor Angels +3
16 Jun 2010
Grant $850.86K 1
National Institute of Diabetes and Digestive and Kidney Diseases
01 Aug 2009
Debt Financing $1.12M -
29 Jul 2009
Grant $1.55M 1
National Institute of Diabetes and Digestive and Kidney Diseases
15 Sep 2008
Series C Undisclosed 1
Cherrystone Angel Group
01 May 2008
Grant $335.07K 1
National Institute of Diabetes and Digestive and Kidney Diseases
01 Apr 2008
Grant $283.52K 1
National Institute of Diabetes and Digestive and Kidney Diseases
01 Aug 2007
Grant $872.23K -
27 Jul 2007
Series C $1.22M -
11 Apr 2007
Grant $394.36K -
01 Apr 2007

SmartCells Alternatives & Competitors

View All Alternatives
SmartCells vs

Science & Excellence

Private Equity
379 employees
Biopharma, Biotechnology
SmartCells vs
Abdera Therapeutics
Abdera Therapeutics United States

Abdera Therapeutics Inc. is a precision oncology company developing next-generation targeted radiati...

Series B
36 employees
Biotechnology, Health Care
SmartCells vs

Biotechnologia w trosce o pacjenta

Private Equity
257 employees
Biopharma, Biotechnology

FAQ About SmartCells

Innovative insulin solutions for diabetes and advanced polymer-based dosing for comprehensive medical applications.
SmartCells was founded in 2003.
SmartCells operates in Biotechnology and Health Care. Its work centres on insulin products, diabetes management, injectable formulation and polymer-based dosing.
SmartCells has completed 10 funding rounds, raising a total of $10.72M. The latest funding stage is Series D.
Top alternatives and competitors to SmartCells include Gan & Lee Pharmaceuticals, Abdera Therapeutics, BIOTON S.A., Chesson Laboratory Associates, Inc., ViaCyte. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
SmartCells and Gan & Lee Pharmaceuticals are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Source: BounceWatch company record for SmartCells, https://bouncewatch.com/company/smartcells, updated 26 December 2024. When citing, please name BounceWatch and link this page.

Analytics cookies (ours + Google). Cookie Policy

Book a demo 30 minutes